Brashear A
Department of Neurology, Indiana University Medical Center, Indianapolis 46202-5250, USA.
Semin Neurol. 2001;21(1):85-90. doi: 10.1055/s-2001-13123.
The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of toxins, botulinum toxin type A (BTX-A) and botulinum toxin type B (BTX-B), have each been studied in large multicenter trials in subjects with CD. A study of BTX-A demonstrated improvement of 5.15 to 10.65 degrees in head position using the Cervical Dystonia Severity Scale (CDSS) in those treated with BTX-A (trade name BOTOX) compared with placebo. A study in patients who continued to respond to BTX-A and a similarly designed study in patients who were resistant to BTX-A demonstrated statistical improvement in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in those treated with BTX-B (evaluated as NeuroBloc) compared with placebo. The potential availability of both forms of toxin will allow physicians to offer further treatment options to patients with CD.
使用肉毒杆菌毒素治疗颈部肌张力障碍(CD)显著改善了患有这种致残性且常伴有疼痛疾病的患者的生活质量。两种形式的毒素,A型肉毒杆菌毒素(BTX-A)和B型肉毒杆菌毒素(BTX-B),都已在针对CD患者的大型多中心试验中进行了研究。一项关于BTX-A的研究表明,与安慰剂相比,使用BTX-A(商品名保妥适)治疗的患者,根据颈部肌张力障碍严重程度量表(CDSS),头部位置改善了5.15至10.65度。一项针对持续对BTX-A有反应的患者的研究以及一项针对对BTX-A耐药的患者的类似设计研究表明,与安慰剂相比,使用BTX-B(评估为NeuroBloc)治疗的患者在多伦多西部痉挛性斜颈评定量表(TWSTRS)上有统计学上的改善。两种毒素形式的潜在可用性将使医生能够为CD患者提供更多的治疗选择。